Page last updated: 2024-08-24

plerixafor and cytarabine

plerixafor has been researched along with cytarabine in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (6.67)29.6817
2010's14 (93.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bridger, G; DiPersio, JF; Holt, MS; Ley, TJ; Nervi, B; Piwnica-Worms, D; Prior, JL; Ramirez, P; Rettig, MP; Ritchey, JK; Uy, GL1
Abboud, CN; Cashen, AF; DiPersio, JF; Hladnik, LM; Kulkarni, S; McFarland, K; Motabi, IH; Rettig, MP; Stockerl-Goldstein, KE; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P1
Andreeff, M; Hatanaka, Y; Hsu, FJ; Jin, L; Konopleva, M; Miida, T; Shi, YX; Shikami, M; Tabe, Y; Zeng, Z1
Bonferroni, M; Borra, A; Castellino, C; Celeghini, I; Di Marco, C; Fiore, F; Gallamini, A; Ghiglia, A; Grasso, M; Marenchino, D; Mattei, D; Mordini, N; Rapezzi, D; Sorasio, R; Strola, G1
Annesley, CE; Brown, P; Li, L; Magoon, D; Rau, RE; Sison, EA; Small, D1
Kong, P; Li, J; Ma, Y; Shen, Z; Zeng, D; Zhang, C; Zhang, X; Zhu, L; Zou, Z1
Han, AR; Kim, HJ; Kim, SH; Lee, JY; Min, WS; Park, G1
Kong, PY; Ma, YY; Shen, ZH; Zeng, DF; Zhang, X1
Abboud, CN; Andreeff, M; DiPersio, JF; Eades, W; Fletcher, TR; Jacoby, MA; Konopleva, MY; McFarland, K; Reineck, T; Rettig, MP; Shannon, W; Stockerl-Goldstein, K; Stone, RM; Uy, GL; Westervelt, P1
Binner, M; Bornhäuser, M; Bray, LJ; Körner, Y; von Bonin, M; Werner, C1
Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T1
Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S1
Han, AR; Hwang, HS; Kim, HJ; Lee, JY; Min, WS; Park, GS1

Reviews

1 review(s) available for plerixafor and cytarabine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

5 trial(s) available for plerixafor and cytarabine

ArticleYear
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
    Blood, 2012, Apr-26, Volume: 119, Issue:17

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Receptors, CXCR4; Remission Induction; Salvage Therapy; Survival Rate; Young Adult

2012
Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Biomarkers; Cyclams; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Time Factors; Transplantation, Autologous

2014
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.
    Blood cancer journal, 2017, 03-10, Volume: 7, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; Cyclams; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Stem Cell Transplantation

2017
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co
    Pediatric blood & cancer, 2017, Volume: 64, Issue:8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Child; Child, Preschool; Cyclams; Cytarabine; Etoposide; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR4; Treatment Outcome; Young Adult

2017
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Annals of hematology, 2018, Volume: 97, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult

2018

Other Studies

9 other study(ies) available for plerixafor and cytarabine

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.
    Blood, 2009, Jun-11, Volume: 113, Issue:24

    Topics: Animals; Anti-HIV Agents; Antimetabolites, Antineoplastic; Apoptosis; Benzylamines; Bone Marrow; Cathepsin G; Cathepsins; Colony-Forming Units Assay; Cyclams; Cytarabine; Drug Synergism; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Leukemia, Experimental; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Protein Transport; Receptors, CXCR4; Serine Endopeptidases; Stromal Cells; Tumor Cells, Cultured

2009
TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Marrow; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Coculture Techniques; Cyclams; Cytarabine; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Mice, SCID; Neoplasm Transplantation; Receptors, CXCR4; Transforming Growth Factor beta; Tumor Microenvironment

2013
Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
    Oncotarget, 2014, Oct-15, Volume: 5, Issue:19

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylamines; Cell Adhesion Molecules; Cell Line, Tumor; Chemokine CXCL12; Chemotaxis; Coculture Techniques; Cyclams; Cytarabine; Heterocyclic Compounds; Heterografts; Humans; Infant; Infant, Newborn; Integrin alpha4beta1; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR; Receptors, CXCR4; Up-Regulation

2014
[Effects of SDF-1/CXCR4 signal pathway blockade by AMD3100 on the adhesion of leukemia cells to osteoblast niche and the drug resistance of leukemia cells].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:5

    Topics: Apoptosis; Benzylamines; Cell Adhesion; Cell Line, Tumor; Chemokine CXCL12; Coculture Techniques; Cyclams; Cytarabine; Drug Resistance; Flow Cytometry; Heterocyclic Compounds; Humans; Leukemia; Mesenchymal Stem Cells; Osteoblasts; Receptors, CXCR4; Signal Transduction

2015
A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
    Oncology reports, 2015, Volume: 34, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Benzylamines; Bone Marrow Cells; Cell Movement; Chemokine CXCL12; Cyclams; Cytarabine; Female; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Neoplasms, Experimental; Neoplastic Stem Cells; Receptors, CXCR4; Tumor Microenvironment

2015
AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds.
    Blood cells, molecules & diseases, 2016, Volume: 59

    Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Biomimetic Materials; Cell Adhesion; Cell Movement; Cells, Cultured; Chemokine CXCL12; Cyclams; Cytarabine; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Leukemia; Leukemia, Myeloid, Acute; Polystyrenes; Receptor Cross-Talk; Receptors, CXCR4; Stromal Cells

2016
A three-dimensional
    Haematologica, 2017, Volume: 102, Issue:7

    Topics: Benzylamines; Biomarkers; Cell Communication; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cyclams; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Heterocyclic Compounds; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Receptors, CXCR4; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment

2017
Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
    Immunological investigations, 2019, Volume: 48, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Benzylamines; Cell Line, Tumor; Cyclams; Cytarabine; Disease Models, Animal; Heterocyclic Compounds; Humans; Immunomodulation; Immunotherapy; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Myeloid Progenitor Cells; Receptors, CXCR4; Tumor Microenvironment

2019